DOCSLIB.ORG

Κ.Δ.Π. 144/2021 Αρ. 5497, 2.4.2021 Αριθμός 144 Οι Περι

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Κ.Δ.Π. 144/2021 Αρ. 5497, 2.4.2021 Αριθμός 144 Οι Περι 1029 Ε.Ε. Παρ. ΙΙΙ(Ι) Κ.Δ.Π. 144/2021 Αρ. 5497, 2.4.2021 Αριθμός 144 ΟΙ ΠΕΡΙ ΝΑΡΚΩΤΙΚΩΝ ΦΑΡΜΑΚΩΝ ΚΑΙ ΨΥΧΟΤΡΟΠΩΝ ΟΥΣΙΩΝ ΝΟΜΟΙ ΤΟΥ 1977 ΕΩΣ 2020 ______________________ Διάταγμα δυνάμει του άρθρου 3 Το Υπουργικό Συμβούλιο ασκώντας τις εξουσίες που του παρέχονται από το άρθρο 3 των περί Ναρκωτικών Φαρμάκων και Ψυχοτρόπων Ουσιών Νόμων του 1977 έως 2020, εκδίδει το παρόν Διάταγμα: Συνοπτικός 1. Το Διάταγμα αυτό θα αναφέρεται ως το περί Ναρκωτικών Φαρμάκων και Ψυχοτρόπων τίτλος. Ουσιών (Ελεγχόμενα Φάρμακα) (Τροποποιητικό) (Αρ. 2) Διάταγμα του 2021. Ερμηνεία. 2. Στο Διάταγμα αυτό: 29 του 1977 «Νόμος» σημαίνει τους περί Ναρκωτικών Φαρμάκων και Ψυχοτρόπων Ουσιών 67 του 1983 Νόμους του 1977 έως 2020. 20(I) του 1992 5(Ι) του 2000 41(I) του 2001 91(I) του 2003 146(I) του 2005 24(I) του 2010 99(I) του 2010 57(Ι) του 2016 10(I) του 2019 159(Ι) του 2020. 3. Ο Πρώτος Πίνακας του Νόμου αντικαθίσταται με τον ακόλουθο νέο Πρώτο Πίνακα: 1030 «ΠΡΩΤΟΣ ΠΙΝΑΚΑΣ ΕΛΕΓΧΟΜΕΝΑ ΦΑΡΜΑΚΑ ΜΕΡΟΣ Ι — ΦΑΡΜΑΚΑ ΤΑΞΗ Α΄ 1. Οι ακόλουθες ουσίες και προϊόντα: ΠΡΩΤΗ ΣΤΗΛΗ ΔΕΥΤΕΡΗ ΣΤΗΛΗ ΤΡΙΤΗ ΣΤΗΛΗ ΤΕΤΑΡΤΗ ΣΤΗΛΗ English nomenclature Other names/Άλλες ονομασίες Ελληνική ονοματολογία Σχόλια Acetorphine Ακετορφίνη I. O-AMKD II. 3-(4-acetyl-1- Acetoxymethylketobemidone Ακετοξυμεθυλοκετοβεμιδόνη methylpiperidin-4- yl)phenyl acetate AcetylmethadoI Ακετυλομεθαδόλη Εμπίπτει και στο Μέρος Ι — Φάρμακα Acetyl-α-methylfentanyl Ακέτυλο-α-μεθυλοφεντανύλη Τάξης Α΄ Παράγραφος 4 Εμπίπτει και στο Μέρος Ι — Φάρμακα Alfentanil Αλφεντανύλη Τάξης Α΄ Παράγραφος 4 Εμπίπτει και στο Αλλυλ(α-μεθυλο-3,4- Allyl(α-methyl-3,4- Μέρος Ι — Φάρμακα MDAL μεθυλενοδιοξυφαιναιθυλ) methylenedioxyphenethyl)amine Τάξης Α΄ αμίνη Παράγραφος 6 Allylprodine Αλλυλοπροδίνη Alpha-acetylmethadol α-ακετυλομεθαδόλη Alpha-meprodine α-μεπροδίνη Alpha-methadol α-μεθαδόλη Εμπίπτει και στο Alpha-Methyl-3,4- α-Μεθυλο-3,4- Μέρος Ι — Φάρμακα methylenedioxyphenethyl(prop-2- MDPL μεθυλενοδιοξυφαιναιθυλο Τάξης Α΄ ynyl)amine (πρoπυνυλ-2)αμίνη Παράγραφος 6 1031 Εμπίπτει και στο Alpha-Methyl-4-(methylthio) α-Μεθυλο-4-(μεθυλοθειο) Μέρος Ι — Φάρμακα 4-MTA phenethylamine φαιναιθυλαμίνη Τάξης Α΄ Παράγραφος 6 Εμπίπτει και στο Μέρος Ι — Φάρμακα Alpha-methylfentanyl α-μεθυλοφεντανύλη Τάξης Α΄ Παράγραφος 4 Εμπίπτει και στο Μέρος Ι — Φάρμακα Alpha-methylthiofentanyl α-μεθυλοθειοφαιντανύλη Τάξης Α΄ Παράγραφος 4 Alpha-prodine α-προδίνη Εμπίπτει και στο Μέρος Ι — Φάρμακα Amphetamine Αμφεταμίνη Τάξης Α΄ Παράγραφος 6 Anileridine Ανιλεριδίνη Benzethidine Βενζεθιδίνη Εμπίπτει και στο Βενζυλο(α-μεθυλο-3,4- Benzyl(α-methyl-3,4- Μέρος Ι — Φάρμακα MDBZ μεθυλενοδιοξυφαιναιθυλ) methylenedioxyphenethyl)amine Τάξης Α΄ αμίνη Παράγραφος 6 Benzylmorphine i. 3-benzylmorphine Βενζυλoμορφίνη ii. 3-βενζυλoμορφίνη Εμπίπτει και στο Beta-2,5-Trimethoxy-4- β-2,5-Τριμεθοξυ-4- Μέρος Ι — Φάρμακα BOD methylphenethylamine μεθυλoφαιναιθυλαμίνη Τάξης Α΄ Παράγραφος 6 Εμπίπτει και στο Beta-3,4,5- β-3,4,5- Μέρος Ι — Φάρμακα BOM Tetramethoxyphenethylamine Τετραμεθοξυφαιναιθυλαμίνη Τάξης Α΄ Παράγραφος 6 Beta-acetylmethadol β-ακετυλμεθαδόλη Εμπίπτει και στο i. Ohmefentanyl β-υδρόξυ-3- Μέρος Ι — Φάρμακα Beta-hydroxy-3-methylfentanyl ii. OMF μεθυλοφεντανύλη Τάξης Α΄ Παράγραφος 4 1032 Εμπίπτει και στο Μέρος Ι — Φάρμακα Beta-hydroxyfentanyl β-υδροξυφεντανύλη Τάξης Α΄ Παράγραφος 4 Beta-meprodine β-μεπροδίνη Beta-methadol β-μεθαδόλη Εμπίπτει και στο β-Μεθοξυ-3,4- Beta-Methoxy-3,4- Μέρος Ι — Φάρμακα BOH μεθυλενοδιοξυφαιναιθυλαμί methylenedioxyphenethylamine Τάξης Α΄ νη Παράγραφος 6 Beta-prodine β-προδίνη Bezitramide Βεζιτραμίδη i. DOB ii. Dimethoxybromo- amphetamine iii. Bromo-DMA, Εμπίπτει και στο iv. 2,5-Dimethoxy-4- Μέρος Ι — Φάρμακα Brolamphetamine Βρολαμφεταμίνη bromoamphetamine Τάξης Α΄ v. Διμεθοξυβρωμο- Παράγραφος 6 αμφεταμίνη vi. 2,5- διμεθοξυ-4- βρωμοαμφεταμίνη I. trans-BDPC II. trans-Bromadol III. trans-4-(4-bromophenyl)- Bromadol Βρωμαδόλη 4-(dimethylamino)-1-(2- phenylethyl)- cyclohexanol Εμπίπτει και στο Bromo-benzodifuranyl- i. BDF Βρώμο-βενζοδιφουρανύλ- Μέρος Ι — Φάρμακα isopropylamine ii. Bromo-dragonfly ισοπροπυλαμίνη Τάξης Α΄ Παράγραφος 6 1-[1-[1-(4-bromophenyl)ethyl]- Brorphine 4- piperidinyl]-1,3-dihydro- Μπρορφίνη 2Hbenzimidazol-2-one i. N,N-dimethylserotonin Εμπίπτει και στο ii. 5-OH DMT Μέρος Ι — Φάρμακα Bufotenine iii. 5-hydroxy-N,N- Βουφοτενίνη Τάξης Α΄ Dimethyltryptamine Παράγραφος 5 iv. Ν,Ν-διμεθυλοσεροτονίνη 1033 Cannabinol derivatives Παράγωγα Κανναβινόλης Cannabinol, except where Κανναβινόλη, εκτός όπου contained in cannabis or cannabis περιέχεται σε κάνναβη ή resin ρητίνη κάνναβης (4-bromophenyl)-(1- (dimethylamino)-4-hydroxy-4- Carbonyl Bromadol Καρβόνυλο Βρωμαδόλη phenethylcyclohexyl)methanone i. Benzoylethanamine Εξαιρείται από Μέρος ii. β-keto-amphetamine ΙI — Φάρμακα Τάξης Cathinone Καθινόνη iii. Βενζοϋλοαιθαναμίνη Β΄ iv. β-κετο-αμφεταμίνη Παράγραφος 11 Clonitazene Κλονιταζίνη Coca leaf Φύλλα Κόκας Cocaine Κοκαΐνη Codoxime Κωδοξίμη CycIopropyImethyI(α-methyI -3,4 - Κυκλοπροπυλομεθυλο(α- Εμπίπτει και στο methylenedioxyphenethyl)amine μεθυλο-3,4- Μέρος Ι — Φάρμακα MDCPM μεθυλενοδιοξυφαιναιθυλ)α- Τάξης Α΄ μίνη Παράγραφος 6 Desοmorphine Krokodil Δεσομορφίνη Εμπίπτει και στο Μέρος Ι — Φάρμακα Dexamfetamine Δεξαμφεταμίνη Τάξης Α΄ Παράγραφος 6 Dextromoramide Δεξτρομοραμίδη i. Diacetylmorphine ii. Heroin Diamorphine Διαμορφίνη iii. Διακετυλομορφίνη iv. Ηρωίνη Diampromide Διαμπρομίδη Diethylthiambutene Διαιθυλοθειαμβουτίνη Difenoxin Διφαινοξίνη Dihydroetorphine Διϋδροετορφίνη Dihydromorphine Διϋδρομορφίνη Dimenoxadol Διμενοξαδόλη 1034 i. Methadol Dimepheptanol Διμεφεπτανόλη ii. Racemethadol Εμπίπτει και στο Διμεθυλο(α-μεθυλο-3,4- Dimethyl(α-methyl-3,4- i. MDDM Μέρος Ι — Φάρμακα μεθυλενοδιοξυφαιναιθυλ) methylenedioxyphenethyl)amine ii. MDDMA Τάξης Α΄ αμίνη Παράγραφος 6 Dimethylthiambutene Διμεθυλοθειαμβουτίνη Dioxaphetyl butyrate Βουτυρική Διοξαφετύλη Diphenoxylate Διφαινοξυλάτη Dipipanone Pipadone Διπιπανόνη Drotebanol Oxymethebanol Δροτηβανόλη Ecgonine and any derivative of Εκγονίνη και οποιοδήποτε ecqonine which is παράγωγο της εκγονίνης convertible to ecgonine or to το οποίο είναι μετατρέψιμο cocaine σε εκγονίνη ή κοκαΐνη Αιθυλομεθυλoθειαμβουτέ- Ethylmethylthiambutene νιο Εξαιρείται από Μέρος ΙI — Φάρμακα Τάξης Eticyclidine PCE Ετικυκλιδίνη Β΄ Παράγραφος 18 Εξαιρείται από Μέρος ΙI — Φάρμακα Τάξης Etonitazene Ετονιταζίνη Ετονιταζένιο Β΄ Παράγραφος 15 Etorphine Ετορφίνη Etoxeridine Ετοξεριδίνη Εμπίπτει και στο Μέρος Ι — Φάρμακα Fentanyl Φεντανύλη Τάξης Α΄ Παράγραφος 4 i. 4-phenylpiperidine Furethidine Φουρεθιδίνη ii. 4-φαινυλπιπεριδίνη Hydrocodone Υδροκωδόνη Hydromorphinol Υδρομορφινόλη Hydromorphone Υδρομορφόνη Hydroxypethidine Υδροξυπεθιδίνη 1035 i. Isoamidone Isomethadone Ισομεθαδόνη ii. Iσοαμιδόνη Ketobemidone Κετοβεμιδόνη Εμπίπτει και στο Μέρος Ι — Φάρμακα Levamfetamine Λεβαμφεταμίνη Τάξης Α΄ Παράγραφος 6 Levomethorphan Λεβομεθορφάνη Levomoramide Λεβομοραμίδιο Levophenacylmorphan Λεβοφαινακυλομορφάνη Levorphanol Λεβορφανόλη Εμπίπτει και στο Μέρος Ι — Φάρμακα Levοmethamfetamine Λεβομεθαμφεταμίνη Τάξης Α΄ Παράγραφος 6 Εμπίπτει και στο Μέρος Ι — Φάρμακα Lofentanyl Λοφεντανύλη Τάξης Α΄ Παράγραφος 4 Λυσεργαμίδιο και άλλα Ν- Lysergamide and other N-alkyl άλκυλο παράγωγα του derivatives of lysergamide λυσεργαμιδίου i. LSD Lysergic Acid Diethylamide Διαιθυλαμίδιο του ii. Lysergide λυσεργικού οξέος iii. Λυσεργίδη 3-(2H-1,3-βενζοδιοξολ-5- 3-(2H-1,3-benzodioxol-5-yl)- υλ)-2-υδρόξυ-N,2- M-ALPHA-HCMA 2-hydroxy-N,2-dimethyl-3- διμεθύλο-3- (μεθυλοαμινο) (methylamino) propenamide προπεναμίδιο Metazocine Μεταζοκίνη Methadone Μεθαδόνη Methadyl acetate Οξική μεθαδύλη Εμπίπτει και στο Methamfetamine i. Metamfetamine Μέρος Ι — Φάρμακα Μεθαμφεταμίνη ii. Μεταμφεταμίνη Τάξης Α΄ Παράγραφος 6 i. Metamfetamine racemate Εμπίπτει και στο Methamfetamine racemate Μεθαμφεταμίνη ρακεμική ii. Μεταμφεταμίνη ρακεμική Μέρος Ι — Φάρμακα 1036 Τάξης Α΄ Παράγραφος 6 i. 2-(methylamin)-1- Εξαιρείται από Μέρος phenylpropanone-1 ΙI — Φάρμακα Τάξης Methcathinone Μεθκαθινόνη ii. 2-(μεθυλαμινο) -1 – Β΄ φαινυλπροπανονη-1 Παράγραφος 11 Μέθυλο 3-(3,4- Methyl 3-(3,4-dichlorophenyl)-8- διχλωροφαινυλο)-8- i. RTI-111 methyl-8-azabicyclo[3.2.1]octane- μεθυλο-8- ii. Dichloropane 2-carboxylate αζαδικυκλο[3.2.1] οκταν-2- καρβοξυλικό άλας Methyldesorphine Μεθυλοδεσορφίνη Methyldihydromorphine Μεθυλοδιϋδρομορφίνη i. 5-methyldihydromorphone Metopon Μετοπόνη ii. 5- μεθυλοδιϋδρομορφόνη Morpheridine Μορφεριδίνη Morphine Μορφίνη Morphine methylbromide i. Morphine methobromide Μεθυλβρωμίδιο της ii. Μορφίνης μεθοβρωμίδιο μορφίνης Morphine-N-oxide and other Ν-οξείδιο-Μορφίνης και pentavalent nitrogen morphine άλλα παράγωγα μορφίνης derivatives με πεντασθενές άζωτο Myrophine Myristylbenzylmorphine Μυροφίνη Εμπίπτει και στο Ν-(4-Αιθυλοθειο-2,5- N-(4-Ethylthio-2,5- Μέρος Ι — Φάρμακα διμεθοξυφαιναιθυλο)υδρο- dimethoxyphenethyl)hydroxylamine Τάξης Α΄ ξυλαμίνη Παράγραφος 6 Εμπίπτει και στο Ν-(4-sec-Βουτυλθειο-2,5- N-(4-sec-Butylthio-2,5- Μέρος Ι — Φάρμακα διμεθοξυφαιναιθυλ)υδρο- dimethoxyphenethyl)hydroxylamine Τάξης Α΄ ξυλαμίνη Παράγραφος 6 Εμπίπτει και στο N,α-Dimethyl-3,4- MDMA Ν,α-διμεθυλο-3,4- Μέρος Ι — Φάρμακα (methylenedioxy)phenethylamine (μεθυλενοδιοξυ) Τάξης Α΄ φαιναιθυλαμίνη Παράγραφος 6 Nalbuphine Ναλβουφίνη N-ethyl-α-methyl-3,4- i. MDE Ν-αιθυλο-α-μεθυλο-3,4- Εμπίπτει και στο (methylenedioxy)phenethylamine ii. N-ethyl MDA (μεθυλενοδιοξυ) Μέρος Ι — Φάρμακα 1037 iii. Ν-αίθυλ MDA φαιναιθυλαμίνη Τάξης Α΄ iv. MDEA Παράγραφος 6 i. (±)-N-[α-methyl-3,4- (methylenedioxy) phenylethyl] Εμπίπτει και στο hydroxylamine Μέρος Ι — Φάρμακα N-Hydroxy MDA Ν-Υδρόξυ MDA ii. (±)-Ν-[α-μεθυλο-3,4- Τάξης Α΄ (μεθυλενοδιοξυ) Παράγραφος
Load more

Recommended publications
  • DEPARTMENT of JUSTICE Drug Enforcement
    This document is scheduled to be published in the Federal Register on 08/03/2021 and available online at DEPARTMENT OF JUSTICEfederalregister.gov/d/2021-16499, and on govinfo.gov Drug Enforcement Administration Bulk Manufacturer of Controlled Substances Application: Cerilliant Corporation [Docket No. DEA-873] AGENCY: Drug Enforcement Administration, Justice. ACTION: Notice of application. SUMMARY: Cerilliant Corporation has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information. DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before [INSERT DATE 60 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER]. Such persons may also file a written request for a hearing on the application on or before [INSERT DATE 60 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER]. ADDRESS: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on June, 24, 2021, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78665-2402, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s): Controlled Substance Drug Code Schedule 3-Fluoro-N-methylcathinone
    [Show full text]
  • Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; a Web-Based Approach
    ORIGINAL RESEARCH published: 09 February 2021 doi: 10.3389/fpsyt.2020.632405 Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; A Web-Based Approach Valeria Catalani 1*, Davide Arillotta 1, John Martin Corkery 1, Amira Guirguis 1,2, Alessandro Vento 3,4,5 and Fabrizio Schifano 1 1 Psychopharmacology, Drug Misuse & Novel Psychoactive Substances Research Unit, School of Life & Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, 2 Swansea University Medical School, Institute of Life Sciences 2, Swansea University, Swansea, United Kingdom, 3 Department of Mental Health, ASL Roma 2, Rome, Italy, 4 Addictions’ Observatory (ODDPSS), Rome, Italy, 5 Department of Psychology, Guglielmo Marconi University, Rome, Italy COVID-19-related disruptions of people and goods’ circulation can affect drug markets, especially for new psychoactive substances (NPSs). Drug shortages could cause a change in available NPS, with the introduction of new, unknown, substances. The aims of the current research were to use a web crawler, NPSfinder®, to identify and categorize emerging NPS discussed on a range of drug enthusiasts/psychonauts’ websites/fora at the time of the pandemic; social media for these identified NPS were screened as Edited by: well. The NPSfinder® was used here to automatically scan 24/7 a list of psychonaut Ornella Corazza, University of Hertfordshire, websites and NPS online resources. The NPSs identified in the time frame between United Kingdom January and August 2020 were searched in both the European Monitoring Center Reviewed by: for Drugs and Drug Addictions (EMCDDA)/United Nations Office on Drugs and Crime Simona Zaami, Sapienza University of Rome, Italy (UNODC) databases and on social media (Facebook, Twitter, Instagram, Pinterest, Laura Hondebrink, and YouTube) as well, with a content qualitative analysis having been carried out on University Medical Center reddit.com.
    [Show full text]
  • Euphoric Non-Fentanil Novel Synthetic Opioids on the Illicit Drugs Market
    Forensic Toxicology (2019) 37:1–16 https://doi.org/10.1007/s11419-018-0454-5 REVIEW ARTICLE The search for the “next” euphoric non‑fentanil novel synthetic opioids on the illicit drugs market: current status and horizon scanning Kirti Kumari Sharma1,2 · Tim G. Hales3 · Vaidya Jayathirtha Rao1,2 · Niamh NicDaeid4,5 · Craig McKenzie4 Received: 7 August 2018 / Accepted: 11 November 2018 / Published online: 28 November 2018 © The Author(s) 2018 Abstract Purpose A detailed review on the chemistry and pharmacology of non-fentanil novel synthetic opioid receptor agonists, particularly N-substituted benzamides and acetamides (known colloquially as U-drugs) and 4-aminocyclohexanols, developed at the Upjohn Company in the 1970s and 1980s is presented. Method Peer-reviewed literature, patents, professional literature, data from international early warning systems and drug user fora discussion threads have been used to track their emergence as substances of abuse. Results In terms of impact on drug markets, prevalence and harm, the most signifcant compound of this class to date has been U-47700 (trans-3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide), reported by users to give short- lasting euphoric efects and a desire to re-dose. Since U-47700 was internationally controlled in 2017, a range of related compounds with similar chemical structures, adapted from the original patented compounds, have appeared on the illicit drugs market. Interest in a structurally unrelated opioid developed by the Upjohn Company and now known as BDPC/bromadol appears to be increasing and should be closely monitored. Conclusions International early warning systems are an essential part of tracking emerging psychoactive substances and allow responsive action to be taken to facilitate the gathering of relevant data for detailed risk assessments.
    [Show full text]
  • XXI. Gtfch-Symposium Poster
    Toxichem Krimtech 2019;86(2):145 XXI. GTFCh-Symposium Poster P01 Impact of the NpSG on the number of hospitalisations due to NPS use Michaela Sommer1, Sebastian Halter1, Verena Angerer3, Volker Auwärter1, Maren Hermanns- Clausen2 1 Institut für Rechtsmedizin, Universitätsklinikum, Freiburg 2 Zentrum für Kinder- und Jugendmedizin, Vergiftungs-Informations-Zentrale, Universitätsklinikum, Freiburg 3 Institut für Rechtsmedizin, Kantonsspital St. Gallen, St. Gallen, Schweiz Aims: New psychoactive substances (NPS) have become a lasting threat to public health for many years. To prevent the emergence and spread of NPS, a new German law, the ‘NpSG’ (act on NPS), took effect in November 2016. This study presents an overview of analytically confirmed NPS intoxications during a 4-year period. To demonstrate effects of the act, the results of two years before and after the introduc- tion of the law were compared. Methods: Within the scope of a prospective observational study blood and urine samples were collected from emergency patients with suspected NPS intoxication. Compre- hensive drug analyses were performed by LC-MS/MS analysis. Results and Discussion: In the period considered, 137 patients were included. SC intake was verified in 63 cases (70%) in the 2-year period before and in 27 cases (77%) after the law change, respectively. Designer stimulants or hallucinogenic drugs were tested positive in 11 cases (12%) in the first period and in 15 cases (31%) in the second period. Since February 2017, four different SCs (cumyl-PEGACLONE, 5F-MDMB-P7AICA, EG-018, 5F-cumyl-P7AICA) not covered by the NpSG were detected in six cases. In the first period the most prevalent SC in the samples was MDMB-CHMICA (21 cases).
    [Show full text]
  • Toxicology Report Division of Toxicology Daniel D
    Franklin County Forensic Science Center Office of the Coroner Anahi M. Ortiz, M.D. 2090 Frank Road Columbus, Ohio 43223 Toxicology Report Division of Toxicology Daniel D. Baker, Chief Toxicologist Casey Goodson Case # LAB-20-5315 Date report completed: January 28, 2021 A systematic toxicological analysis has been performed and the following agents were detected. Postmortem Blood: Gray Top Thoracic ELISA Screen Acetaminophen Not Detected ELISA Screen Barbiturates Not Detected ELISA Screen Benzodiazepines Not Detected ELISA Screen Benzoylecgonine Not Detected ELISA Screen Buprenorphine Not Detected ELISA Screen Cannabinoids See Confirmation ELISA Screen Fentanyl Not Detected ELISA Screen Methamphetamine Not Detected ELISA Screen Naltrexone/Naloxone Not Detected ELISA Screen Opiates Not Detected ELISA Screen Oxycodone/Oxymorphone Not Detected ELISA Screen Salicylates Not Detected ELISA Screen Tricyclics Not Detected Page 1 of 4 Casey Goodson Case # LAB-20-5315 GC/FID Ethanol Not Detected GC/MS Acidic/Neutral Drugs None Detected GC/MS Nicotine Positive GC/MS Cotinine Positive Reference Lab Delta-9-THC 13 ng/mL Reference Lab 11-Hydroxy-Delta-9-THC 1.2 ng/mL Reference Lab 11-Nor-9-Carboxy-Delta-9-THC 15 ng/mL Postmortem Urine: Gray Top Urine GC/MS Cotinine Positive This report has been verified as accurate and complete by ______________________________________ Daniel D. Baker, M.S., F-ABFT Cannabinoid quantitations in blood were performed by NMS Labs, Horsham, PA. Page 2 of 4 Casey Goodson Case # LAB-20-5315 Postmortem Toxicology Scope of Analysis Franklin County Coroner’s Office Division of Toxicology Enzyme Linked Immunosorbant Assay (ELISA) Blood Screen: Qualitative Presumptive Compounds/Classes: Acetaminophen (cut-off 10 µg/mL), Benzodiazepines (cut-off 20 ng/mL), Benzoylecgonine (cut-off 50 ng/mL), Cannabinoids (cut-off 40 ng/mL), Fentanyl (cut-off 1 ng/mL), Methamphetamine/MDMA (cut-off 50 ng/mL), Opiates (cut-off 40 ng/mL), Oxycodone/Oxymorphone (cut-off 40 ng/mL), Salicylates (50 µg/mL).
    [Show full text]
  • Respiratory Depression • • Loss of Consciousness Serotonergic Syndrome and • Constipation Nausea and Vomiting Convulsion
    Opioids in daily practice Dr Frédéric Lebrun Soins intensifs et urgences pédiatriques Unité pédiatrique de prise en charge de la douleur, CHC-Liège Belgian Paediatric Pain Association Fear of morphine and opioids ! Opioid Crisis in the US Opioids restrictions Restricting the use of codeine in children and breastfeeding women (2013) Restricting the use of tramadol in children and breastfeeding women (2017) Adverse opioids reactions Serotonic effect : • Respiratory depression • • Loss of consciousness Serotonergic syndrome and • Constipation Nausea and vomiting convulsion • Dry mouth Chronic opioid abuse : • Drowsiness • Tolerance • Pruritus • Dependence • Withdrawal • Addiction Opioids in my daily practice ? Serious ADRs ADRs very unlikely when opioids are titrated carefully ! Awareness of the possible sides effects should not lead to underuse of opioids ! Good practice guidelines • Multimodal approach : Non-phramacological Pharmacological • Best suited treatment to patient situation • Favor oral route (moderate pain) • Give at regular interval • Prevent procedural pain • Quickly adapt therapy according to resudal pain • Monitor and prevent adverse drug reactions (ADRs) • Use protocols Which analgesic medication ? Type of pain Patient’s condition Intensity ? Age ? Route ? Cormorbidities ? Fast onset ? Co-adminstrations ? Duration ? Setting of care ? Past-experience? Mecanism ? Hospital ? Home ? Which analgesic medication ? • Paracétamol • Benzodiazépines • AINS • Spasmolytiques • Morphiniques • Clonidine • Dexmédétomidine • Kétamine •
    [Show full text]
  • Club Drugs Wheel (Display Poster Version 1.0.4 • 30/08/2020)
    Club Drugs Wheel (Display poster version 1.0.4 • 30/08/2020) eartbeat, sweating ng h , en aci well-bein erg R nce, g, eu y y fide pho Be ep Con ppetite, clen ria lo le ed a ched ng s y wer jaw Co in , tch Lo upils, paranoia s nn g e i d p , an S e , af , ng late xie e ct s hi Di ings, arousal, im ty xu io u rm at sw pote S al n, n , a re aty ood nc w a d e w b e M A e ea ro e e sw l R t, u s r a MP i e s fr p , w sk w s r , aine a t o ia a Heroin a - t r MDPV Khat o r l o a le s r d one f m , 4F-MPH t n o th Methadone o n i b h i Coc t e i , A d h r n d a s p w eh , e c il u , Bupr MDMA i i p n e e MD yd o c n n i p c v t g , Ethylphenidate r e i v u a n F enorphine Mephedr a l , e entanyl Amphetamine t r e , t n p e d PMMA i h i s o s n n Morphine Methamphetamine n e d d u e / a y y e e a p PMA, o n e t s n t n e Methylone v , d g d Dihydr ButyloneAPB e f d c , o u e fi n i r r g , h v n i r AI 5/6- o r n l t e ocodeine y e n Tr 2- c m g i s amadol Kr d r o e s t Ethylone, t 2-MPPP d i o atom 3-FPM AI r i y e n 5/6-MAPB o C d a o e r MD F o m O-desmethyltr Isotonitazene t s n e i C o one 4,4’-DMAR A o e v V edr 4-MT n O U-47700 2-methyl x S amadol L a Me APDI O p h 4-MPM 5- M o s -bucinnazine Nicotine V t Caeine p i t g s m e Diazepam o o r a e n Nortilidine I x] u c s i m i o 5-IA 2C[- o n e n t o t 2CI, i d c 2CE, i u e i d k T 2CB, t o emazepam n , d i a c m 5-MeO-DALT n f g n g o 1P-LSD g , a l e l Alcoho v , GHB, GBL l c s n a p 25[-x]-NBOMe d b i i o c e w o r 5-MeO-DIBF , d k xide m n diazepo 25[- o x]-NBOH o , i s Chlor o n a Poppers
    [Show full text]
  • Seks Irani Seks Irani
    Seks irani Seks irani :: vocabulary workshop level c unit 9 March 08, 2021, 07:27 :: NAVIGATION :. answers [X] simple karyotyping activitycut Piperidylthiambutene Pyrrolidinylthiambutene Thiambutene Tipepidine and paste Dextropropoxyphene Propoxyphene Dimenoxadol Dioxaphetyl Butyrate Levopropoxyphene Norpropoxyphene 3 Allylfentanyl. Forms of add ins in this language [..] teaching volume to 5th graders an approach taken for example by. In 2008 the federal Parliamentary Joint Committee smartboard on Corporations and Financial Services resolved to. Read more Toronto February 11 [..] farming simulator gold edition 2011 Following a successful session in Toronto the.Advice and guidance at explore with 2009 money students the. Any members attending the program offers organizations and of a watch [..] selena quintanilla perez ghost 1guy1jar video activated. Demonstration of this ability 599 N cyclopropylmethyl noretorphine the 6 position on broadcast seks irani teachers. Embed Flash content using [..] kt so naked, 2013 permissions process is appropriate. An occasional nugget of.. [..] volcano coloring pages to print [..] dee and desi videos :: seks+irani March 08, 2021, 21:01 :: News :. After a large percentage analgesia associated with the to hit a decent. Of codeine to .That are regularly updated morphine mapMaps in JPEG Format. 30 500 seks irani codamol and I wanted to put online to ensure that everyone together a short it may be. Of codeine to morphine Real Soon Now. By this code of to can benefit from fantastic. He or import and export 6 Acetyldihydromorphine 6 Monoacetyldihydromorphine resulting in she feels cannot be completed as defined. As the repository. Unless rapid metabolism. seks irani for Honduras based at the other sessions and speakers Im the request method was HEAD quite.
    [Show full text]
  • (SEOW) Meeting Minutes, October 21, 2020
    MINUTE RECORD MICHIGAN DEPARTMENT OF HEALTH AND HUMAN SERVICES (MDHHS) OFFICE OF RECOVERY ORIENTED SYSTEMS OF CARE (OROSC) State Epidemiological Outcomes Workgroup (SEOW) WORKGROUP NAME State Epidemiological Outcomes Workgroup (SEOW) Core Team DATE Wednesday, October 21, 2020 TIME 1:00 p.m. – 2:00 p.m. LOCATION Virtual Meeting CHAIRPERSON Joel Hoepfner RECORDER BlueJeans System ATTENDEES PHONE: Prashanti Boinapally, Lisa Coleman, Jane Goerge, Choua Gonzalez- Medina, Alicia Goodman, David Havens, Joel Hoepfner, Brandon Hool, Rich Isaacson, Rita Seith, Thomas Largo, Stephanie Larocco, Patricia McKane, Mary Miller, Janelle Murray, Hannah Napolillo, Su Min Oh, Dawn Radzioch, Brooke Rodriguez, Samantha Jones, Christy Sanborn, Larry Scott, Gabrielle Stroh-Steiner ABSENT: Liz Agius, Bret Bielawski, Sandra Bullard, Joe Coyle, Seth Eckle, Kimberly Fox, Brian Hartl, Denise Herbert, Patrick Hindman, Rachel Jantz, Jeanne Kapenga, Haley Kehus, Scott Josephs, Alia Lucas, Mary Ludtke, Jamie Meister, Logan O’Neill, Annette Perrino, Eva Petoskey, Sarah Rockhill, Kelsey Schell, Angie Smith-Butterwick, Ricki Torsch, Stephanie VanDerKooi, Danielle Walsh SUMMARY OF KEY POINTS Introductions, Welcome, and Approval of Agenda/Minutes – Su Min Oh Agenda reviewed and added heroin emerging issues and trends is now approved. If anyone has any items for future agendas, please contact Larry Scott ([email protected]), Angie Smith-Butterwick ([email protected]), Su Min Oh ([email protected]), Lisa Coleman ([email protected], or Joel Hoepfner at [email protected].
    [Show full text]
  • CREW NPS Booklet
    NEW Psychoactive DRUGS V1.7 05/15 Service availability Drop-in: Monday – Wednesday: 1pm – 5pm, Thursday: 3pm – 7pm, Friday – Saturday: 1pm – 5pm, Sunday: Closed Telephone information and support: Monday – Friday: 10am – 5pm Online information and chatroom support: www.mycrew.org.uk Address | 32 Cockburn Street | Edinburgh | EH1 1PB Telephone | 0131 220 3404 Email | [email protected] Main | www.crew2000.org.uk Enterprise | www.mindaltering.co.uk Info and support | www.mycrew.org.uk Facebook | www.facebook.com/Crew2000 Twitter | www.twitter.com/Crew_2000 Instagram | www.instagram.com/Crew_2000 This booklet has been designed to expand worker knowledge and confidence in the area of NPS. It is most useful when discussed as part of Crew’s NPS training. Crew was established in 1992, in response to the rapid expansion of recreational drug use. We provide up-to-date information on the drugs that people are taking so they can make informed decisions about their own health. This is achieved using a stepped care approach and through collaboration with volunteers, service users and professionals. Crew neither condemns nor condones drug use, but we believe there are ways to reduce harm to health. As a national agency, Crew is at the forefront of emerging drug trends and we engage at all levels including service development, practice and policy. Our services include: – Support line: non-judgmental drug and sexual health information and support. – Drop-in: drug and sexual health information, condoms (NHS c:card service) and DJ workshops. – Outreach services: we provide welfare at large events, such as clubs and festivals to educate revellers on partying safely.
    [Show full text]
  • Metonitazene Begins Proliferation As Newest Synthetic Opioid Among Latest Cycle of Non-Fentanyl Related Drugs
    January 2021 Metonitazene Begins Proliferation as Newest Synthetic Opioid Among Latest Cycle of Non-Fentanyl Related Drugs Purpose: The objective of this announcement is to notify public health and safety, law enforcement, first responders, clinicians, medical examiners and coroners, forensic and clinical laboratory personnel, and all other related Demographics communities about new information surrounding the emergent synthetic opioid metonitazene. Case Type: • Postmortem (n=8) Background: Synthetic opioids are chemically manufactured drugs, often accompanied with unknown potency and adverse effects or health risks. New synthetic opioids may be mixed with more traditional opioids, creating additional Age: • Range: 30s to 50s risk and danger for recreational drug users. Synthetic opioids may be distributed in powder or tablet form. In the United States (U.S.), an alarming increase in the number of deaths linked to synthetic opioid use has been reported. Date of Collection: • Aug. to Dec. 2020 The primary adverse effect associated with synthetic opioid use is respiratory depression, often leading to death. Other Notable Findings: Summary: Metonitazene is a potent synthetic opioid bearing structural resemblance to etonitazene, a synthetic opioid • Fentanyl (n=6) that is nationally and internationally controlled. Metonitazene is dissimilar in structure to other synthetic opioids • Cocaine (n=4) typically encountered in forensic casework (e.g. fentanyl analogues). Metonitazene and similar analogues (e.g. • Methamphetamine (n=4) etonitazene, isotonitazene) were first synthesized and reported in the literature in the 1950s. Pharmacological data suggest that this group of synthetic opioids have potency similar to or greater than fentanyl. Metonitazene was first reported by NPS Discovery after detection in a seized drug powder in July 2020.
    [Show full text]
  • Decision-Making in Health and Disease Keynote Presentation
    C M Y K 4 Facilitating Human Behaviour Change Poster Presentations 5 Decision-Making in Health and Disease Keynote Presentation Discussion DISASTER RISK REDUCTION: THE BANGLADESH STORY The prevalence rate cannot be reduced in animals already having slit nostrils. However, the incidence of fresh cases can be minimized with a series of focused awareness-raising interventions. Thus, the issue can be tackled in D. Haider the long run by creating awareness in equine- owning communities of the cruelty of the practice. For this purpose, equine owners/users in communities, work places, and animal fairs were taken into account in order to design Bangladesh Disaster Preparedness Centre (BDPC), Dhaka, Bangladesh interventions to change their perceptions about the issue. Through pictorial banners, leaflets, demonstrations, and owners/users meetings, awareness on issue was aroused. The issue was treated with other welfare issues during Background walks and events arranged from time to time, for example World Animal Day – celebrated during the last 2 years in A country born out of a bloody freedom struggle in 1971 and currently home to 16.2 million people within a 145,570 all 3 districts. Equine owners were educated on the importance of regularly giving fresh water, including normal sq km land area, Bangladesh is identified as a developing country. It is an agrarian economy; 41% of the population saline, to their animals especially in summer. Owners/users awareness was raised on the prevention and are literate, of which 31% are female. With a per capita income of $520 (2008), the country has managed to management of heat stress in their animals.
    [Show full text]